Reference health
Therapeutic Antibodies for the Treatment of Respiratory Tract Infections—Current Overview and Perspectives
71/71 checkable references clean · checked 2026-07-23
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
13 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 71 checked references that resolve
resolves10.1513/AnnalsATS.201312-420PS
Lung Disease in a Global Context. A Call for Public Health Action
resolves10.1016/S0140-6736(16)31593-8
Global, regional, and national causes of under-5 mortality in 2000–15: an updated systematic analysis with implications for the Sustainable Development Goals
resolves10.1038/s41541-017-0019-3
Antibody therapies for the prevention and treatment of viral infections
resolves10.3389/fimmu.2018.02700
Combination of Antibodies and Antibiotics as a Promising Strategy Against Multidrug-Resistant Pathogens of the Respiratory Tract
resolves10.1080/19420862.2016.1196521
Therapeutic monoclonal antibodies for respiratory diseases: Current challenges and perspectives, March 31 – April 1, 2016, Tours, France
resolves10.4161/mabs.25300
Therapeutic antibodies and infectious diseases, Tours, France, November 20−22, 2012
resolves10.1001/jama.1922.02640050005003
CLINICAL AND BACTERIOLOGIC STUDY OF ONE THOUSAND CASES OF LOBAR PNEUMONIA
resolves10.1016/j.tim.2015.07.005
Antiviral Monoclonal Antibodies: Can They Be More Than Simple Neutralizing Agents?
resolves10.1038/256495a0
Continuous cultures of fused cells secreting antibody of predefined specificity
resolves10.1016/j.pharmthera.2018.05.003
Therapeutic antibodies: A new era in the treatment of respiratory diseases?
resolves10.1073/pnas.0909775106
Precise determination of the diversity of a combinatorial antibody library gives insight into the human immunoglobulin repertoire
resolves10.1016/j.molimm.2015.03.255
Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases
resolves10.1007/s40262-020-00874-2
Pharmacokinetic Variability of Therapeutic Antibodies in Humans: A Comprehensive Review of Population Pharmacokinetic Modeling Publications
resolves10.1128/CMR.00010-16
Respiratory Syncytial Virus: Infection, Detection, and New Options for Prevention and Treatment
resolves10.1128/JVI.02140-15
Respiratory Syncytial Virus Attachment Glycoprotein Contribution to Infection Depends on the Specific Fusion Protein
resolves10.1038/s41467-019-12137-1
A potent broadly neutralizing human RSV antibody targets conserved site IV of the fusion glycoprotein
resolves10.1016/S0140-6736(10)60206-1
Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis
resolves10.1097/INF.0000000000001916
Safety, Tolerability and Pharmacokinetics of MEDI8897, an Extended Half-life Single-dose Respiratory Syncytial Virus Prefusion F-targeting Monoclonal Antibody Administered as a Single Dose to Healthy Preterm Infants
resolves10.1093/ofid/ofy210.1215
1384. RSV Monoclonal Antibody (MK-1654) Phase 1 Pharmacokinetics (PK) in Healthy Adults and Population PK Modeling to Support Pediatric Development
resolves10.1158/2326-6066.CIR-15-0059
Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti–PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells
resolves10.1186/s40425-019-0603-3
Safety and clinical activity of PD-L1 blockade in patients with aggressive recurrent respiratory papillomatosis
resolves10.1016/j.coi.2018.04.010
Improving influenza vaccines: challenges to effective implementation
resolves10.1016/j.ebiom.2016.02.021
Safety and Upper Respiratory Pharmacokinetics of the Hemagglutinin Stalk-Binding Antibody VIS410 Support Treatment and Prophylaxis Based on Population Modeling of Seasonal Influenza A Outbreaks
resolves10.1016/j.ebiom.2018.12.051
Safety and efficacy of monoclonal antibody VIS410 in adults with uncomplicated influenza A infection: Results from a randomized, double-blind, phase-2, placebo-controlled study
resolves10.1016/j.antiviral.2019.104562
New antibody-based prevention and treatment options for influenza
resolves10.3389/fimmu.2020.01626
Overview: Systemic Inflammatory Response Derived From Lung Injury Caused by SARS-CoV-2 Infection Explains Severe Outcomes in COVID-19
resolves10.1016/j.cell.2020.04.026
Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19
resolves10.3390/vaccines8020224
Recent Insight into SARS-CoV2 Immunopathology and Rationale for Potential Treatment and Preventive Strategies in COVID-19
resolves10.1016/j.cellsig.2020.109721
Drugs targeting various stages of the SARS-CoV-2 life cycle: Exploring promising drugs for the treatment of Covid-19
resolves10.1016/S2665-9913(20)30173-9
Tocilizumab in patients with severe COVID-19: a retrospective cohort study
resolves10.1101/2020.04.01.20048561
IL-6 signalling pathway inactivation with siltuximab in patients with COVID-19 respiratory failure: an observational cohort study
resolves10.1016/S0140-6736(09)61114-4
Pathogenesis, treatment, and prevention of pneumococcal pneumonia
resolves10.1128/AAC.01102-16
Obiltoxaximab Prevents Disseminated Bacillus anthracis Infection and Improves Survival during Pre- and Postexposure Prophylaxis in Animal Models of Inhalational Anthrax
resolves10.1002/cpdd.410
Safety, Pharmacokinetics, and Immunogenicity of Obiltoxaximab After Intramuscular Administration to Healthy Humans
resolves10.1128/CMR.00134-14
Staphylococcus aureus Infections: Epidemiology, Pathophysiology, Clinical Manifestations, and Management
resolves10.1586/ers.12.45
Management and prevention of ventilator-associated pneumonia caused by multidrug-resistant pathogens
resolves10.1038/nrmicro.2017.27
Leukocidins: staphylococcal bi-component pore-forming toxins find their receptors
resolves10.1128/AAC.02456-16
Targeting Alpha Toxin To Mitigate Its Lethal Toxicity in Ferret and Rabbit Models of Staphylococcus aureus Necrotizing Pneumonia
resolves10.1128/AAC.00510-15
MEDI4893* Promotes Survival and Extends the Antibiotic Treatment Window in a Staphylococcus aureus Immunocompromised Pneumonia Model
resolves10.1128/AAC.03918-14
Anti-Alpha-Toxin Monoclonal Antibody and Antibiotic Combination Therapy Improves Disease Outcome and Accelerates Healing in a Staphylococcus aureus Dermonecrosis Model
resolves10.1164/ajrccm-conference.2019.199.1_MeetingAbstracts.A7358
Suvratoxumab Reduces Staphylococcus Aureus Pneumonia in High-Risk ICU Patients: Results of the SAATELLITE Study
resolves10.1164/rccm.200408-1044SO
Pathogen–Host Interactions in
<i>Pseudomonas aeruginosa</i>
Pneumonia
resolves10.1007/s10096-014-2156-1
Assessment of panobacumab as adjunctive immunotherapy for the treatment of nosocomial Pseudomonas aeruginosa pneumonia
resolves10.1016/j.mib.2007.09.010
Role of polysaccharides in Pseudomonas aeruginosa biofilm development
resolves10.1016/j.jaip.2018.11.024
Allergic bronchopulmonary aspergillosis successfully treated with benralizumab
resolves10.1128/AAC.01714-16
Safety, Tolerability, and Pharmacokinetics of MEDI8897, the Respiratory Syncytial Virus Prefusion F-Targeting Monoclonal Antibody with an Extended Half-Life, in Healthy Adults
resolves10.1007/s40262-018-0680-3
Influence of Antigen Mass on the Pharmacokinetics of Therapeutic Antibodies in Humans
resolves10.1128/AAC.06446-11
Population Pharmacokinetics of Palivizumab, a Humanized Anti-Respiratory Syncytial Virus Monoclonal Antibody, in Adults and Children
resolves10.1038/psp.2013.14
Basic Concepts in Population Modeling, Simulation, and Model‐Based Drug Development—Part 2: Introduction to Pharmacokinetic Modeling Methods
resolves10.1111/j.1365-2958.2011.07942.x
<i>Staphylococcus aureus</i> leucocidin ED contributes to systemic infection by targeting neutrophils and promoting bacterial growth <i>in vivo</i>
resolves10.1016/j.biotechadv.2017.03.011
Very-large-scale production of antibodies in plants: The biologization of manufacturing
resolves10.1128/AAC.00897-19
Cost-Effectiveness of Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant
<i>Enterobacteriaceae</i>
Bacteremia and Pneumonia
resolves10.1016/j.jconrel.2019.04.005
In a murine model of acute lung infection, airway administration of a therapeutic antibody confers greater protection than parenteral administration
The 13 references without a DOI — listed, not checked
no DOI — not checkedFoundation, W.L. (2010). Acute Respiratory Infections Atlas, World Lung Foundation.
no DOI — not checked[Monoclonal antibodies in infectious diseases: New partners in the therapeutic arsenal]
no DOI — not checkedWorld Health Organization (2020, October 30). Global Influenza Strategy 2019–2030. Available online: https://www.who.int/influenza/global_influenza_strategy_2019_2030/en/.
no DOI — not checkedNext-generation direct-acting influenza therapeutics
no DOI — not checkedOldach, D., Narayan, K., Schaefers, K., Sloan, S., Smith, P., Bliss, R., Arbrough, J., and Shriver, Z. (2019). A global, randomised, dou-ble-blind, placebo-controlled study evaluating safety and efficacy of vis410 in combination with oseltamivir versus oselta-mivir alone in hospitalized adults with influenza a requiring oxygen. Option X for the Control of Influenza, International Society for Influenza and other Respiratory Virus Diseases (ISIRV).
no DOI — not checkedU.S. Food and Drug Administration (2021, January 12). Emergency Use Authorization, Available online: https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization#covid19euas.
no DOI — not checkedBaron, S. (1996). Infections of the respiratory system. Medical Microbiology, University of Texas Medical Branch at Gavelston. [4th ed.].
no DOI — not checkedGBD Lower Respiratory Infections Collaborators (2018). Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet Infect. Dis., 18, 1191–1210.
no DOI — not checkedHendricks, K., Vieira, A.R., and Marston, C.K. (2020, October 30). Anthrax, Available online: https://wwwnc.cdc.gov.
no DOI — not checkedStaphylococcus aureus Pore-Forming Toxins
no DOI — not checkedNewswire, P. (2021, February 13). Presents Positive Phase 2a Safety and Efficacy Data of Salvecin™ (AR-301) in Patients with Severe Pneumonia Caused by Staphylococcus aureus During the 2017 ASM Microbe Congress. Available online: https://www.prnewswire.com/.
no DOI — not checkedKhan, A., Yu, X.Q., François, B., Eggimann, P., Huberlant, V., Dequin, P.F., Valia, J.C., Ali, S.O., Jensen, K., and Colbert, S. (2018, January 21–24). Interim pharmacokinetic analysis from the SAATELLITE Phase 2 Clinical Trial of Suvratoxumab (MEDI4893), an extended half-life monoclonal antibody against Staphylococcus aureus alpha toxin. Proceedings of the 28th ECCMID, Madrid, Spain.
no DOI — not checkedO’Neill, J. (2016). Tackling Drug-Resistant Infections Globally: Final Report and Recommendations, Wellcome Trust UK Department of Health.
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-23 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.3390/vaccines9020151"><img src="https://citestamp.com/citestamped/10.3390/vaccines9020151/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.3390/vaccines9020151)